Cargando…

The Anti-Influenza Virus Drug Favipiravir Has Little Effect on Replication of SARS-CoV-2 in Cultured Cells

Detalles Bibliográficos
Autores principales:	Tomita, Yuriko, Takeda, Makoto, Matsuyama, Shutoku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092917/ https://www.ncbi.nlm.nih.gov/pubmed/33649117 http://dx.doi.org/10.1128/AAC.00020-21

Ejemplares similares

Frequent occurrence of mutations in nsp3 and nsp4 of SARS-CoV-2, presumably caused by the inhaled asthma drug ciclesonide
por: Doi, Akihiro, et al.
Publicado: (2022)

The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells
por: Matsuyama, Shutoku, et al.
Publicado: (2020)

Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico
por: Sada, Mitsuru, et al.
Publicado: (2020)

Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways
por: Iwata-Yoshikawa, Naoko, et al.
Publicado: (2022)

Enhancement of SARS-CoV Infection by Proteases
por: Matsuyama, Shutoku, et al.
Publicado: (2006)

The mechanism of resistance to favipiravir in influenza
por: Goldhill, Daniel H., et al.
Publicado: (2018)

ICU admission and favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Favipiravir use for SARS CoV-2 infection
por: Boretti, Alberto
Publicado: (2020)

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
por: Shiraki, Kimiyasu, et al.
Publicado: (2020)

Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model
por: Chiba, Shiho, et al.
Publicado: (2022)

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
por: Kaptein, Suzanne J. F., et al.
Publicado: (2020)

Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir
por: Peng, Qi, et al.
Publicado: (2021)

Hematological Malignancy Patients, COVID-19, and Favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Anti-Influenza Virus Study of Composite Material with MIL-101(Fe)-Adsorbed Favipiravir
por: Xu, Mengyuan, et al.
Publicado: (2022)

Preliminary investigation of drug impurities associated with the anti-influenza drug Favipiravir – An insilico approach
por: Anil Kumar, S., et al.
Publicado: (2021)

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
por: Matsuyama, Shutoku, et al.
Publicado: (2020)

Favipiravir elicits antiviral mutagenesis during virus replication in vivo
por: Arias, Armando, et al.
Publicado: (2014)

Model of the RNA Polymerase Complex of the SARS-CoV-2 Virus with Favipiravir
por: Polyakov, I. V., et al.
Publicado: (2021)

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
por: Solaymani-Dodaran, Masoud, et al.
Publicado: (2021)

Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
por: Korman, Tony M.
Publicado: (2021)

Attenuation of SARS‐CoV‐2 replication and associated inflammation by concomitant targeting of viral and host cap 2'‐O‐ribose methyltransferases
por: Bergant, Valter, et al.
Publicado: (2022)

Physicochemical Characteristics and In Vitro Toxicity/Anti-SARS-CoV-2 Activity of Favipiravir Solid Lipid Nanoparticles (SLNs)
por: Tulbah, Alaa S., et al.
Publicado: (2021)

Favipiravir Experience in Covid-19 Positive Myasthenia Gravis Patients
por: Yevgi, Recep, et al.
Publicado: (2021)

Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019
por: Kumar, Pramod, et al.
Publicado: (2021)

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients
por: Chen, Ping-Jen, et al.
Publicado: (2021)

Rational Defensive Medicine: Putting an End to the Nationwide Favipiravir Debate
por: Öncel, Selim
Publicado: (2022)

Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase
por: Shannon, A., et al.
Publicado: (2020)

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2021)

Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?
por: Zhao, Lei, et al.
Publicado: (2021)

Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
por: Negru, Paul Andrei, et al.
Publicado: (2022)

Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
por: Hashemian, Seyed MohammadReza, et al.
Publicado: (2022)

The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution
por: Ormond, Louise, et al.
Publicado: (2017)

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19
por: Ison, Michael G., et al.
Publicado: (2021)

Favipiravir-resistant influenza A virus shows potential for transmission
por: Goldhill, Daniel H., et al.
Publicado: (2021)

Use of the particle agglutination/particle agglutination inhibition test for antigenic analysis of SARS‐CoV‐2
por: Kobayashi, Jun, et al.
Publicado: (2023)

Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel
por: LEADBEATER, P D M, et al.
Publicado: (2011)

Comparison of genome replication fidelity between SARS-CoV-2 and influenza A virus in cell culture
por: Kawasaki, Yoshiko, et al.
Publicado: (2023)

Has SARS-CoV-2 evolved and adapted to circulate at high temperatures?
por: Lippi, G., et al.
Publicado: (2022)

From Molière to SARS-CoV-2: How Medicine has changed
por: Perciaccante, A., et al.
Publicado: (2022)

Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19)
por: McCullough, Peter A.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ddc52b6e40a4fpqlds2nd1cvuq